Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10
Aerpio Pharmaceuticals (Nasdaq: ARPO) plans to release its Q3 2020 financial results on November 10, 2020, before the market opens. The company is focused on developing Tie2 activating compounds for treating ocular diseases and diabetic complications, along with potential applications for acute respiratory distress syndrome (ARDS) linked to COVID-19. The conference call will begin at 8:30 AM ET, providing insights into financial performance and future developments.
- Focus on development of Tie2 activating compounds for major therapeutic areas.
- Potential applications for COVID-19 related ARDS, enhancing relevance during the pandemic.
- Diverse pipeline including razuprotafib for glaucoma and ARP-1536 for diabetic complications.
- None.
CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activation of Tie2 may have therapeutic potential, including acute respiratory distress syndrome (“ARDS”) associated with COVID-19 infections, will release its financial results for the third quarter ended September 30, 2020, before the market open on Tuesday, November 10, 2020, and host a webcast and conference call at 8:30am ET.
| Tuesday, November 10th @ 8:30am ET | |
| Investors: | 877-407-9716 |
| International Investors: | 201-493-6779 |
| Conference ID: | 13711910 |
| Audio-Only Webcast: | http://public.viavid.com/index.php?id=141964 |
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activation of Tie2 may have therapeutic potential, including acute respiratory distress syndrome (“ARDS”) associated with COVID-19 infections. Recently published mouse and human genetic data implicate the Angpt/Tie2 pathway in maintenance of Schlemm’s canal, a critical component of the conventional outflow tract. The Company’s lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (“VE-PTP”), is being developed as a potential treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in other indications.. The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema (“DME”). The Company’s third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924’s exclusive licensor, Gossamer Bio, Inc. (Nasdaq: GOSS). For more information, please visit www.aerpio.com.
Investors & Media:
Gina Marek
VP Finance
gmarek@aerpio.com
Or
Investors:
Irina Koffler
LifeSci Advisors
ikoffler@lifesciadvisors.com
FAQ
When will Aerpio Pharmaceuticals release its Q3 2020 financial results?
What is the focus of Aerpio Pharmaceuticals?
What are the potential applications of Aerpio's lead compound, razuprotafib?
What time is the Aerpio Pharmaceuticals conference call?
How can investors access Aerpio Pharmaceuticals' conference call?
